1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
RVL Pharmaceuticals plc

RVL Pharmaceuticals plc

RVLPQ
RVL Pharmaceuticals plcUS flagOther OTC
0.00
USD
- -
- -
1,114.00Market Cap
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
TTM
Revenue per Share
5.1
5.73
5.82
4.58
0.46
0.26
0.55
0.38
Basic EPS, GAAP
-0.98
-0.96
-2.42
-5.17
-1.31
-0.96
-0.58
-0.7
Free Cash Flow per Basic Share
-1.42
1.19
0.74
0.56
0.24
-0.84
-0.43
-0.49
Dividend per Share
0.54
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
-2.24
-7.11
-7.45
-7.67
-6.33
-6.18
Tangible Book Value per Share
-9.08
-7.86
-4.58
-2.68
0.05
-0.09
-0.21
-0.4
Basic Weighted Avg Shares
43
43
45
52
61
67
90
98
Sales/Revenue/Turnover
218
246
264
240
28
18
50
37
Operating Margin (%)
-1
8.51
2.16
1.27
-222.4
-460.03
-91.87
-118.02
Depreciation Expense
24
46
82
57
21
8
- -
- -
Net Income, GAAP
-42
-41
-110
-271
-80
-65
-52
-68
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-19.14
-16.74
-41.59
-112.86
-286.68
-370.95
-103.96
-184.91
Working Capital
-24
-10
58
97
117
39
37
-43
LT Debt
324
314
267
271
220
44
56
- -
Total Equity
465
436
384
115
94
77
51
16
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Dec'22
Mar'23
Jun'23
ST Debt
2
4
58
LT Borrowings
56
53
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
99
99
99
Market Capitalization
101
107
55

Working Capital

FRC

•

in mil. unless spec.
Dec'22
Mar'23
Jun'23
Total Current Assets
57
38
26
Cash, Cash Equivalents & STI
45
33
19
Accounts Receivable, Net
1
- -
1
Inventories
1
- -
1
Total Current Liabilities
20
16
68
Payables & Accruals
12
8
7
ST Debt
2
4
58
Deferred Revenue
2
2
1

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-30.37%
-33.41%
Free Cash Flow
- -
-123.96%
-31.77%
Net Income, GAAP
- -
40.83%
-20.38%
Sales/Revenue/Turnover
- -
11.41%
184.1%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
1
12
2
3
18
2022
21
8
10
10
50
2023
9
8
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
-0.15
-0.28
-0.28
-0.24
-0.96
2022
-0.08
-0.14
-0.16
-0.18
-0.58
2023
-0.12
-0.24
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Brian A. Markison
Full Time Employees
125
Sector
Healthcare
Industry
Biotechnology
Address
400 Crossing Boulevard Bridgewater NJ United States of America 08807
IPO Date
Oct 18, 2018
CIK
0001739426
Website
rvlpharma.com
Similar Companies
Ultimovacs ASA (ULTI.OL)
NewAmsterdam Pharma Company N.V. (NAMSW)
Acelyrin, Inc. (SLRN)
immatics biotechnologies GmbH (IMTXW)
OSR Holdings, Inc. (OSRH)
Cizzle Biotechnology Holdings Plc (CIZ.L)
Business
RVL Pharmaceuticals plc (RVLPQ) is a specialty pharmaceutical company focused on developing and commercializing ophthalmic prescription products for medical conditions including dry eye disease and abnormalities of the eyelids. The company offers Uplizna (a self-microemulsifying drug delivery system formulation of oxymetazoline hydrochloride ophthalmic solution, 0.1%), an alpha-1 adrenergic receptor agonist indicated for the treatment of acquired blepharoptosis in adults; and commercializes other branded ophthalmic products such as KPI-12, which targets meibomian gland dysfunction in adult patients with dry eye disease associated with meibomian gland dysfunction; along with additional offerings in the dry eye and eyelid disorder therapeutic categories. Founded in 2016 and headquartered in Bridgewater, New Jersey, RVL operates primarily in the United States with a focus on ophthalmology markets, targeting healthcare providers and patients requiring treatments for eye-related conditions.